Silver Book Fact

Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.

Wagner E, Sandhu N, Newton K, McCulloch D, et al. Effect of Improved Glycemic Control on Health Care Costs and Utilization. JAMA. 2001; 285(2): 182-189. http://jama.ama-assn.org/cgi/content/abstract/285/2/182

Reference

Title
Effect of Improved Glycemic Control on Health Care Costs and Utilization
Publication
JAMA
Publisher
JAMA
Publication Date
2001
Authors
Wagner E, Sandhu N, Newton K, McCulloch D, et al
Volume & Issue
Volume 285, Issue 2
Pages
182-189
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…